However, SGLT2 inhibitor use is also associated with adverse events including ketoacidosis (30), and was only prescribed off-label for patients with type 1 diabetes, as was also the case for GLP-1 receptor agonists, at the time of data acquisition in Germany, which could explain the low prescription frequency for newly diagnosed type 1 diabetes. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.